Canaccord Genuity Group Has Lowered Expectations for Pulmonx (NASDAQ:LUNG) Stock Price

Pulmonx (NASDAQ:LUNG) had its target price cut by investment analysts at Canaccord Genuity Group from $6.00 to $5.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would suggest a potential upside of 147.52% from the company’s current price.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a research report on Thursday, January 22nd. D. Boral Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of Pulmonx in a research note on Thursday. Finally, Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Five equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Pulmonx has a consensus rating of “Hold” and a consensus price target of $5.38.

Pulmonx Stock Up 25.5%

Pulmonx stock opened at $2.02 on Thursday. The company has a market capitalization of $83.33 million, a PE ratio of -1.52 and a beta of 0.07. Pulmonx has a 12-month low of $1.31 and a 12-month high of $8.12. The firm’s fifty day moving average is $1.75 and its 200 day moving average is $1.79. The company has a quick ratio of 4.15, a current ratio of 4.86 and a debt-to-equity ratio of 0.62.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings results on Wednesday, March 4th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.14. Pulmonx had a negative net margin of 59.67% and a negative return on equity of 78.35%. The business had revenue of $22.60 million during the quarter, compared to analysts’ expectations of $21.73 million. As a group, sell-side analysts predict that Pulmonx will post -1.55 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Glendon E. French III sold 67,813 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $1.43, for a total value of $96,972.59. Following the transaction, the chief executive officer owned 1,409,511 shares of the company’s stock, valued at approximately $2,015,600.73. This trade represents a 4.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders have sold 98,265 shares of company stock valued at $140,519. 6.80% of the stock is currently owned by company insiders.

Institutional Trading of Pulmonx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ExodusPoint Capital Management LP purchased a new stake in shares of Pulmonx in the fourth quarter worth approximately $4,312,000. Vestal Point Capital LP purchased a new position in shares of Pulmonx during the third quarter valued at approximately $1,345,000. State Street Corp grew its holdings in Pulmonx by 3.6% during the fourth quarter. State Street Corp now owns 821,217 shares of the company’s stock worth $1,815,000 after buying an additional 28,813 shares in the last quarter. GSA Capital Partners LLP raised its position in Pulmonx by 78.3% in the 3rd quarter. GSA Capital Partners LLP now owns 755,467 shares of the company’s stock valued at $1,224,000 after buying an additional 331,742 shares during the last quarter. Finally, Bank of America Corp DE raised its position in Pulmonx by 556.6% in the 2nd quarter. Bank of America Corp DE now owns 481,268 shares of the company’s stock valued at $1,246,000 after buying an additional 407,971 shares during the last quarter. 91.04% of the stock is owned by institutional investors.

Key Pulmonx News

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Pulmonx beat Q4 expectations — EPS -$0.25 vs. consensus ~- $0.39 and revenue $22.6M vs. ~$21.7M; net loss narrowed and adjusted EBITDA improved year‑over‑year, signaling operational progress. Read More.
• Positive Sentiment: Closed a five‑year senior secured credit facility with Perceptive Advisors (initial $40M draw; up to $60M total subject to milestones), which refinanced prior debt and extends maturities to 2031 — materially improves near‑term liquidity. Read More.
• Positive Sentiment: Gross margin and cost discipline improved — Q4 gross margin ~78% and operating expenses down ~11% vs. prior year quarter, supporting a clearer path toward profitability if revenue momentum returns. Read More.
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating (high target), which can attract momentum buyers given large upside vs. current levels. Read More.
• Neutral Sentiment: Management outlined a strategic restructuring and sales‑force changes on the earnings call — intended to re‑accelerate commercial growth but the near‑term impact on procedure volumes is unclear. Read More.
• Neutral Sentiment: Some analysts updated targets (Canaccord trimmed its target but kept a Buy rating) — mixed analyst activity keeps coverage but shows differing views on recovery timing. Read More.
• Negative Sentiment: 2026 revenue guidance of $90M–$92M came in below consensus (~$94M), implying slower top‑line growth and limiting near‑term upside despite margin improvements. Read More.
• Negative Sentiment: Insider selling was reported (CEO, general counsel and other officers sold shares on March 2), which can increase perceived selling pressure and weigh on sentiment. Read More.
• Negative Sentiment: The new loan carries a high effective cost (SOFR + 7.0% with 3.75% floor and a 2% PIK option) and includes warrants — helpful for liquidity but increases interest burden and potential dilution if exercised. Read More.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.